Sotera Health Company

NasdaqGS:SHC Stok Raporu

Piyasa değeri: US$4.6b

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Sotera Health Yönetim

Yönetim kriter kontrolleri 3/4

Sotera Health's CEO'su Michael Petras, Jun2016 tarihinde atandı, in görev süresi 8.33 yıldır. in toplam yıllık tazminatı $ 9.70M olup, şirket hissesi ve opsiyonları dahil olmak üzere 10.8% maaş ve 89.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.91% ine doğrudan sahiptir ve bu hisseler $ 90.34M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4 yıl ve 3.9 yıldır.

Anahtar bilgiler

Michael Petras

İcra Kurulu Başkanı

US$9.7m

Toplam tazminat

CEO maaş yüzdesi10.8%
CEO görev süresi8.3yrs
CEO sahipliği1.9%
Yönetim ortalama görev süresi4yrs
Yönetim Kurulu ortalama görev süresi3.9yrs

Son yönetim güncellemeleri

Recent updates

Sotera Health Company's (NASDAQ:SHC) P/S Still Appears To Be Reasonable

Sep 02
Sotera Health Company's (NASDAQ:SHC) P/S Still Appears To Be Reasonable

Sotera Health (NASDAQ:SHC) Takes On Some Risk With Its Use Of Debt

Jun 25
Sotera Health (NASDAQ:SHC) Takes On Some Risk With Its Use Of Debt

Sotera Health Company (NASDAQ:SHC) Shares Could Be 42% Below Their Intrinsic Value Estimate

May 30
Sotera Health Company (NASDAQ:SHC) Shares Could Be 42% Below Their Intrinsic Value Estimate

The Price Is Right For Sotera Health Company (NASDAQ:SHC) Even After Diving 29%

Mar 21
The Price Is Right For Sotera Health Company (NASDAQ:SHC) Even After Diving 29%

Sotera Health Company Just Missed Earnings - But Analysts Have Updated Their Models

Mar 01
Sotera Health Company Just Missed Earnings - But Analysts Have Updated Their Models

McIntyre Partnerships - Sotera Health Company: A Notable Outlier At A Discount

Feb 08

Is Sotera Health (NASDAQ:SHC) A Risky Investment?

Feb 06
Is Sotera Health (NASDAQ:SHC) A Risky Investment?

Investors Still Aren't Entirely Convinced By Sotera Health Company's (NASDAQ:SHC) Revenues Despite 26% Price Jump

Dec 28
Investors Still Aren't Entirely Convinced By Sotera Health Company's (NASDAQ:SHC) Revenues Despite 26% Price Jump

Sotera Health Company's (NASDAQ:SHC) Intrinsic Value Is Potentially 33% Above Its Share Price

Dec 11
Sotera Health Company's (NASDAQ:SHC) Intrinsic Value Is Potentially 33% Above Its Share Price

An Intrinsic Calculation For Sotera Health Company (NASDAQ:SHC) Suggests It's 37% Undervalued

Sep 10
An Intrinsic Calculation For Sotera Health Company (NASDAQ:SHC) Suggests It's 37% Undervalued

Sotera Health Company (NASDAQ:SHC) Shares Could Be 24% Below Their Intrinsic Value Estimate

Jun 05
Sotera Health Company (NASDAQ:SHC) Shares Could Be 24% Below Their Intrinsic Value Estimate

Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 34%?

Feb 13
Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 34%?

Market Participants Recognise Sotera Health Company's (NASDAQ:SHC) Earnings Pushing Shares 29% Higher

Nov 24
Market Participants Recognise Sotera Health Company's (NASDAQ:SHC) Earnings Pushing Shares 29% Higher

Sotera Health plunges 20% after jury awards $363M against its Sterigenics unit

Sep 19

Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 49%?

Sep 08
Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 49%?

Sotera Health GAAP EPS of $0.11 misses by $0.05, revenue of $266.64M beats by $10.34M

Aug 04

CEO Tazminat Analizi

Michael Petras'un ücretlendirmesi Sotera Health'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

US$40m

Mar 31 2024n/an/a

US$55m

Dec 31 2023US$10mUS$1m

US$51m

Sep 30 2023n/an/a

-US$306m

Jun 30 2023n/an/a

-US$268m

Mar 31 2023n/an/a

-US$261m

Dec 31 2022US$17mUS$1m

-US$234m

Sep 30 2022n/an/a

US$121m

Jun 30 2022n/an/a

US$123m

Mar 31 2022n/an/a

US$135m

Dec 31 2021US$2mUS$1m

US$115m

Sep 30 2021n/an/a

US$36m

Jun 30 2021n/an/a

US$9m

Mar 31 2021n/an/a

-US$26m

Dec 31 2020US$17mUS$728k

-US$39m

Sep 30 2020n/an/a

-US$23m

Jun 30 2020n/an/a

-US$28m

Mar 31 2020n/an/a

-US$29m

Dec 31 2019US$2mUS$700k

-US$21m

Tazminat ve Piyasa: Michael 'nin toplam tazminatı ($USD 9.70M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 6.79M ).

Tazminat ve Kazançlar: Michael 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

Michael Petras (55 yo)

8.3yrs

Görev süresi

US$9,701,005

Tazminat

Mr. Michael B. Petras Jr., serves as Chief Executive Officer at Sotera Health Company since June 20, 2016. He has been Chairman of the Board at Sotera Health Company since October 2020. He also served as t...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Michael Petras
Chairman & CEO8.3yrsUS$9.70m1.91%
$ 87.0m
Jonathan Lyons
Senior VP & CFO1.3yrsUS$2.18m0.039%
$ 1.8m
Alexander Dimitrief
Senior VP1.9yrsUS$862.18k0.083%
$ 3.8m
Michael Rutz
President of Sterigenics4yrsUS$2.03m0.17%
$ 7.7m
Robert Hauzie
Chief Information Officer5.8yrsVeri yokVeri yok
Kristin Gibbs
Chief Marketing Officer7.9yrsVeri yokVeri yok
William Lehmann
Senior Vice President of Strategy & Corporate Development2.8yrsVeri yokVeri yok
Sally Turner
Chief Human Resources Officer5.8yrsVeri yokVeri yok
Kathleen Hoffman
Senior Vice President of Global Environmentalno dataVeri yokVeri yok
Joseph Shrawder
President of Nelson Labs4yrsVeri yokVeri yok
Riaz Bandali
President of Nordion2.7yrsVeri yokVeri yok
Jason Peterson
VP & Treasurerno dataVeri yokVeri yok

4.0yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim: SHC 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Michael Petras
Chairman & CEO8.3yrsUS$9.70m1.91%
$ 87.0m
James Neary
Independent Director4yrsUS$320.00k0.015%
$ 668.5k
Constantine Mihas
Independent Director4yrsUS$305.00k0.015%
$ 668.5k
Sean Cunningham
Independent Director4yrsUS$302.50k0.015%
$ 668.5k
Vincent Petrella
Independent Director3.9yrsUS$325.00k0.015%
$ 668.5k
Christopher Simon
Independent Directorless than a yearVeri yokVeri yok
Ann Klee
Independent Director4yrsUS$322.50k0.031%
$ 1.4m
Robert Knauss
Independent Director2yrsUS$300.00k0.0056%
$ 252.9k
Ruoxi Chen
Independent Director3.9yrsUS$302.50k0.015%
$ 668.5k
David Wheadon
Independent Director3.4yrsUS$310.00k0.013%
$ 574.2k
Karen Flynn
Independent Directorless than a yearUS$9.99kVeri yok

3.9yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SHC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.9 yıldır).